Shared on29 Jul 25Fair value Increased 14%
The consensus price target for Akeso has increased, primarily reflecting higher growth expectations as indicated by a substantial rise in the Future P/E, alongside a modestly lower discount rate, resulting in a revised fair value of HK$118.36. What's in the News NMPA accepted Akeso's sNDA for ivonescimab with chemotherapy as first-line treatment for advanced sq-NSCLC following positive Phase III results; ivonescimab now has three accepted applications in China and is in over 12 global Phase III trials across multiple cancers.
Shared on01 May 25Fair value Decreased 1.70%
AnalystConsensusTarget has decreased future PE multiple from 58.2x to 51.2x and decreased shares outstanding growth rate from 0.0% to -0.0%.
Shared on17 Apr 25Fair value Increased 3.75%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Increased 2.39%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.